Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | ELANE | P08246 | 5/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045679 | 0.88 | ELANE (0.54) | GAAMEN1KMT2AL3MBTL1ELANE | |
| SCHEMBL2448079 | 0.87 | ALOX15 (0.57) | MEN1KMT2APTPN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22251779 | 0.87 | HPGD (0.54) | MEN1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL1964630 | 0.86 | PLA2G4B (0.61) | PTPN1HTTMAPK1 | |
| SCHEMBL22000631 | 0.84 | MAPT (0.63) | KMT2AL3MBTL1PTPN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6440664 | 0.84 | PPARA (0.63) | PPARAGAAL3MBTL1ELANEPPARG | |
| SCHEMBL247124 | 0.83 | PTPN1 (0.51) | PPARAKMT2AL3MBTL1PPARGPTPN1 | |
| SCHEMBL7335964 | 0.83 | L3MBTL1 (0.56) | GAAMEN1KMT2AL3MBTL1PTPN1 | |
| SCHEMBL2386974 | 0.83 | SMN1; SMN2 (0.60) | GAAMEN1KMT2AL3MBTL1ELANE | |
| SCHEMBL21936031 | 0.83 | HPGD (0.72) | GAAMEN1KMT2AELANEPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021471-A1 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2011-01-27 | — | — | US | disclosed |
| US-20110021471-A1 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2011-01-27 | — | — | US | disclosed |
| US-20110021471-A1 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2011-01-27 | — | — | US | disclosed |
| WO-2009059239-A2 | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021471-A1 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | APP, BACE1, GAP43 | PPARA 2196/4885GAA 535/4885MEN1 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.